Bevacizumab and Radiation Therapy for Sarcomas

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Soft Tissue SarcomaFibrous HistiocytomaLiposarcomaLeiomyosarcomaFibrosarcomaSynovial Sarcoma
Interventions
DRUG

Bevacizumab

Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses

RADIATION

Radiation Therapy

External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good.

PROCEDURE

Surgery

Surgical resection is performed 6-7 weeks after completion of neoadjuvant therapy.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Massachusetts General Hospital

OTHER

NCT00356031 - Bevacizumab and Radiation Therapy for Sarcomas | Biotech Hunter | Biotech Hunter